

# SUVEN Life Sciences Ltd



## News Release

### **Suven Life Sciences secures Three (3) Indian Product Patents For Their New Chemical Entities (NCEs)**

*HYDERABAD, INDIA (October 23<sup>rd</sup>, 2007) – Suven Life Sciences Ltd (Suven) announces today that the Indian Patent Office had granted three Product Patents 208688, 208714 and 209540 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with Neuro degenerative diseases and these Patents are valid until 2022.*

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like **Alzheimer's, Attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia** .

Suven thus far **has filed 25 product patents** under PCT out of which 10 has entered national phase. These are the first Product Patents granted to Suven from our four years of drug discovery efforts.

Suven has already filed its first **Investigational New Drug (IND)** application with DCGI to conduct the clinical Phase-I study on their developmental candidate **SUVN-502**.

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of Suven.

Suven, since Sept-2006 is also working as a **collaborative Research Partner ( CRP)** with Elli Lilly to Discover and Develop NCEs for an unmet medical need in CNS therapeutic area.

Suven is a major service provider of Drug Discovery and Development support Services (**DDDSS**) to global Pharmaceutical, Life Sciences and Biotech companies in addition to their continued business interest and growth in Contract Research and Manufacturing Services (**CRAMS**).

#### **Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*